Tepotinib, also known as {MSC2156119|the research compound|this agent), represents a promising advance in the targeting of NSCLC, particularly in those harboring MET dysregulation. This selective tyrosine kinase https://deaconoezx599826.wikipresses.com/7295569/tepotinib_a_comprehensive_look_into_msc2156119_and_its_outlook